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The demographics of dyslipidaemia have changed towards a more complex atherogenic dyslipidaemia
involving increased levels of LDL-C, in particular highly atherogenic small dense particles, hyper-
triglyceridaemia and low HDL, together with increased levels of markers of cardiovascular inflam-
mation, thrombogenesis and endothelial dysfunction. Statins were shown to significantly lower 
cardiovascular morbidity and mortality, but there still remains a high residual risk in dyslipidaemic
patients, in particular with metabolic syndrome, type 2 diabetes, or low HDL levels. Fibrates have
been shown to reduce plasma triglycerides and increase HDL-C, while improving inflammation,
thrombogenesis and endothelial dysfunction. Clinical trials with fibrates have demonstrated their
potential to reduce cardiovascular morbidity and mortality too, often through other mechanisms than
these of statins. Combination trials of statins with fibrates have shown a more complete improve-
ment of lipid profile and risk markers than each class separately. In contrast with gemfibrozil, fenofi-
brate does not interact significantly with the pharmacokinetics of statins, and up until now its com-
bination with statins has been shown to have a low risk of muscular side effects or liver toxicity.
The ACCORD outcome trial is exploring the possible benefits of the combination of fenofibrate with
statins on morbidity and mortality of patients with atherogenic dyslipidaemia.





















































































































Over the past 30 years, the demographics of cardio-
vascular (CV) risk have changed. The stereotypic plain
older smoking white male with hypercholesterolaemia
and hypertension was steadily substituted by individu-
als of both sexes and from all socioeconomic strata,
being affected by cardiometabolic risk and indeed sus-
ceptible to its complications, such as coronary disease or
stroke. Obviously, global CV risk includes more than
just dyslipidaemia, but several risk factors such as age,
sex, hypertension, smoking and diabetes, as taken into
account in the European Heart SCORE global risk cal-
culation for individual patients1,2. Despite full avail-
ability of powerful drugs for LDL-cholesterol (LDL-C)
lowering, such as statins, coronary care units remain
filled with individuals with acute coronary syndromes,
yet treated with statins, and whose LDL-C may well
have been within the safe zone according to current
guidelines. We now face a burden of residual CV risk
linked, for instance, to less conventional risk factors
such as atherogenic dyslipidaemia, with low HDL-C,
high triglycerides and atherogenic small dense LDL par-
ticles, with or even without high LDL-C levels, yet asso-
ciated with significant cardiometabolic risk3.
Lipids as a risk factor for cardiovascular disease (CVD)
Many early epidemiological studies have reported
significant associations between serum triglycerides and
coronary artery disease (CAD)4-6. A meta-analysis7 on
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new primary data on 3582 incident cases of CAD and
6175 controls from the European Reykjavik and EPIC-
Norfolk studies showed, after adjustment for baseline
values and several established risk factors, odds ratios
for coronary heart disease linked to triglycerides of 1.76
(95% CI 1.39-2.21) (Reykjavik) and 1.57 (95% CI 1.10-
2.24) (EPIC Norfolk).
An updated meta-analysis in the same paper on 10
158 incident coronary cases from 262 525 participants
in 29 studies (figure 1) found a similar odds ratio of
1.72 (95% CI 1.56-1.90) when comparing the popula-
tion in the upper triglyceride levels tertile with that in
the lower tertile. This largest and most comprehensive
epidemiological assessment on available prospective
studies in Western populations therefore consistently
shows moderately strong but highly significant associ-
ations between triglyceridaemia and CAD risk. The
impact was similar for men and women, in contrast to
previous observations. As can be expected from the
link between triglyceride and HDL-cholesterol path-
ways, adjustment for HDL cholesterol decreased the
magnitude of the association, as evidenced by hetero-
geneity test χ2 = 6.4 with P = 0.01. As can also be
derived from these pooled data, the impact of triglyc-
erides seems even more pronounced in European than
in US populations. The German PROCAM study8
including 4559 participants followed during 6 years
showed similar correlations between triglycerides and
coronary artery disease.
The imbalance between circulating levels of athero-
genic lipoproteins such as LDL, VLDL or IDL,
relative to those of HDL is associated with induction
of endothelial dysfunction, intimately related to inflam-
mation and oxidative stress, and closely related to the
development of atherosclerosis9.
HDL particles possess multiple antiatherogenic 
activities, including reverse cholesterol transport from 
arterial wall to liver for catabolism/excretion, as well 
as antioxidant, anti-inflammatory, anti-apoptotic,
antithrombotic, vasodilatory, and even anti-infectious
properties10. The antioxidant effect of HDL typically
inhibits LDL oxidation, a major physiological target11,
with apolipoprotein A1 (apo-A1) being a major 
component of antioxidative activity11. Among HDL
subfractions, the small and dense HDL3 is the most
potent protector of LDL against oxidation12, through
capture and inactivation of the oxidized lipids in LDL,
ensuring their elimination by transfer to the liver13,14.
Triglyceride enrichment is the most frequent abnor-
mality of HDL lipid composition, as occurs in mixed
hyperlipidaemia (also known as atherogenic dyslipi-
daemia) observed in patients with metabolic syndrome
or type 2 diabetes15. CETP-mediated replacement of
cholesteryl esters with triglycerides in the HDL core
results in decreased plasma HDL-cholesterol levels15.
It could even be a critical factor that lowers both HDL
particle stability and plasma residence time15. From a
functional viewpoint, the capacity of triglyceride-
enriched HDL to deliver cholesteryl esters to hepatic
cells is impaired16 and shifted towards macrophages17,
thus redirecting cholesterol to the inflammatory athero-
matous plaque. It is obvious that in this context, a 



















































































































Fig. 1. – Are triglycerides an independent risk factor?
therapy able to lower triglycerides while improving or
restoring HDL functionality is intuitively worth con-
sidering. Fibrates lower triglyceridaemia by an aver-
age 36%18 and selectively raise small HDL particles
levels19 which are vasculoprotective. In the Veterans
Affairs HDL Intervention trial (VA-HIT), plasma lev-
els of HDL3 were a powerful predictor of cardiovas-
cular risk, suggesting that fibrates are useful in cor-
recting the functionality of small dense HDL14,19.
Prospective studies in several countries provide
compelling evidence for an inverse relationship between
HDL-C levels and cardiovascular risk. This relation-
ship was quantified in an analysis of cohorts from 4
prospective North American studies20. Two of the
cohorts were derived from observational studies, i.e.
the Framingham Heart Study21 and the Lipid Clinics
Follow-up Study22, and two from control groups of
randomized clinical trials in high-risk middle-aged
men, the Multiple Risk Factor Intervention Trial23 and
the Coronary Primary Prevention Trial24. The results
from each cohort were consistent with a decrease of
2-3% in CHD risk for each 1 mg/dL increase in HDL-
C level20. Another study examined the prevalence of
risk factors in 321 men with angiographically docu-
mented coronary disease25. Nearly half of the patients
did not have elevated total cholesterol levels. However,
75% of patients with total cholesterol < 200 mg/dl were
found to have low HDL-C ( < 35 mg/dL). Apparently,
low HDL-C seemed to be the second commonest CHD
risk factor after smoking. For Europe, the European
Consensus Panel on HDL-C26 also concluded to a 2%
increase in CHD for men and 3% for women for each
1 mg/dl decrease in HDL-C. A post-hoc analysis of
the Treatment to New Targets (TNT) study27 showed
HDL-C in patients receiving statins to be predictive of
major cardiovascular events. Even among subjects with
LDL-C below 70 mg/dL, those in the highest quintile
of HDL-C were at less risk than those in the lowest
quintile.
The inverse relationship between HDL-C and CHD
risk also prevails for cerebrovascular accidents. A large
scale survey28 on 7735 men from 24 British towns
showed a significant inverse relationship between
HDL-C levels and risk of stroke (adjusted relative risk
0.68; 95% CI 0.46-0.99), especially for nonfatal strokes
(RR 0.59; 95% CI 0.39-0.90).
Recently, outcome trials29 with the CETP inhibitor
torcetrapib could not confirm the classical inverse rela-
tionship between HDL-C and cardiovascular events.
Possible explanations for this lack of efficacy on mor-
bidity and mortality could be the generation by CETP
inhibition of HDL particles of enlarged size, known to
be less effective in reverse cholesterol transport30.
CETP inhibition also decreases fractional clearance of
apo A-1, increasing the susceptibility of these large
HDL particles to oxidation. Moreover, larger particles
fail to activate endothelial NO synthase through the
Scavenger Receptor class B type 1 (SR-BI) for NO
dependent vasorelaxation31. These changes could
induce thrombogenesis and atherogenesis in some
patients instead of inhibiting it, with neutral or nega-
tive outcome as a result32.
Epidemiology of dyslipidaemia
An epidemiological study (Odyssée) in France33 on
22 323 patients followed by 4000 GPs and 527 cardi-
ologists showed that among dyslipidaemic patients the
prevalence of mixed hyperlipidaemia was 50% and
therefore higher than that of single hypercholestero-
laemia (42%). Drug-based regimens based solely on
LDL-C lowering may just prove insufficient in this
respect, taking into consideration the abovementioned
links between triglycerides, HDL-C and cardiovascu-
lar risk. Mixed hyperlipidaemia is also becoming
increasingly common, as is the prevalence of the meta-
bolic syndrome (MetS) phenotype, itself associated
with abdominal obesity, insulin resistance, and risk of
developing abnormal glucose homeostasis, including
the common form of type 2 diabetes mellitus34. A sur-
vey on 62 254 individuals in France35 showed an
increase from 11% to 13% in the prevalence of meta-
bolic syndrome in men, according to ATP III criteria,
and from 7% to 9% in women over a mere 3 years of
follow-up.
A systematic review and meta-analysis of 37 lon-
gitudinal studies36 including 43 cohorts and 172 573
individuals, showed a relative risk of MetS for cardio-
vascular events and death of 1.78 (95% CI 1.58-2.00).
The significant association remained after adjusting
for traditional cardiovascular risk factors. When MetS
was split into its various discrete components and their
relative risks for myocardial infarction calculated37, it
appears that the sole two variables having significant
odds ratios for that endpoint were high triglyceride 
levels (OR 1.51; 95% CI 1.04-2.20) and low HDL-C
(OR 1.41; 95% CI 1.03-1.95). Diabetes mellitus,
another common discrete component of the MetS is a
standard risk factor for CVD, and its presence
increases such risk twofold in men and fourfold in
women1,38,39.
Have statins solved all problems? Is everything under
control?
There is strong evidence from several mega-trials that
statins effectively lower LDL-C and hence reduce car-
diovascular morbidity and mortality. Although much
emphasis was put on a maximal lowering of LDL-C,
albeit without taking into account other lipid parame-
ters, mortality was typically decreased by 25-35%, but
not further, as shown in figure 2. PROVE-IT/TIMI-2240



















































































































has revealed that lowering of LDL-C < 70 mg/dL further
reduced cardiovascular endpoints, but could not elimi-
nate residual cardiovascular risk. At the same time, upti-
tration of statins ended up with a flattening of their
dose-response curve, making the therapeutic benefit of
such dose increases limited, and the risk of adverse
events, such as myopathy, higher41.
Even under maximal therapy with statins, patients
are left with a major residual relative risk of 62%-82%.
When the effects of statins are split into subgroups of
patients with high or with low HDL-C, discrepancies
in absolute risk reduction do appear, as shown in 
figure 3.
Thus, although the overall magnitude of risk 
reduction with statins appears to be similar for both 
subgroups, the baseline risk of the low HDL-C subgroup
is higher, and the treated group ends up at the risk level
of control groups with high HDL-C. This clearly invites
to consider a therapeutic intervention to bring HDL-C
to higher levels.
In diabetic patients the Collaborative Atorvastatin
Diabetes Study (CARDS)42 showed statin therapy to
significantly reduce cardiovascular events by 37% in
patients without high LDL-C (117 mg/dL). LDL-C was
lowered 40% in the statin arm, supporting the concept
for LDL-C of “the lower the better”. In the ASCOT-
LLA study43,44, statin efficacy appeared to be lower in
type 2 diabetes patients and even lower in patients with
MetS than in the normal population, albeit non sig-
nificantly. Again, both types of patients have the typi-
cal atherogenic triad of low HDL-C, high triglycerides
and small dense LDL particles, where statins prefer-
ably lowers the latter of the three lipid parameters. The
question that arises is therefore whether fibrates can be
of further benefit in such a setting.
Mode of action of fibrates
Fibrates are synthetic carboxylic acids that behave as
peroxisome proliferator activating receptor α
ligands (PPARα), forming heterodimers with another
nuclear receptor partner, the retinoid X receptor,
and subsequently binding to specific PPAR response 
elements (PPREs) in the promoter region of target
genes, thereby regulating gene function. PPARα are
found in tissues where fatty acid catabolism is important,
such as liver, heart, kidney and muscle, and regulate
genes involved in lipid and lipoprotein metabolism45.
PPARα is markedly expressed in the liver, where it
enhances fatty acids uptake, activation and oxidation. It
also does so in other non-white adipose tissue (non-
WAT) organs. PPARα expression is correlated with ele-
vated mitochondrial and peroxisomal b-oxidation activ-
ities in tissues which primarily use fatty acids for ATP
production. It functions in a complementary and tis-
sue-specific manner with PPARb/d in skeletal muscle.
With respect to lipid physiology, the expression of
lipoprotein lipase is enhanced and hepatic apolipopro-
tein CIII expression is decreased. The effects on lipids
and lipoproteins can be globally summarized as fol-
lows46 (figure 4):
1) induction of lipoprotein lipolysis,
2) induction of hepatic cellular fatty acid uptake
(through, for instance, induction of FATP1 and
CPTI) and b-oxidation,
3) reduction of hepatic triglyceride and VLDL pro-
duction,
4) increased removal of LDL particles,
5) reduction in cholesterol and triglyceride
exchange between VLDL and HDL,
6) increase in HDL production and stimulation of
reverse cholesterol transport. HDL-cholesterol
is increased through transcriptional induction
of the synthesis of the major HDL apolipopro-
teins apoA-I and apoA-II, as well as ATP-bind-
ing cassette A1 (ABCA1),
7) fibrates lower the levels of small dense LDL, but
not that of the light, buoyant, LDL fraction,
which is less susceptible to oxidation46 and could
be considered as the most vascular-friendly frac-
tion of LDLs.
PPARα agonism with fibrates also shows
“pleiotropic” effects. Fibrates have vascular effects and
counteract many components of the atherosclerotic
cascade. They improve exercise-induced flow-mediated
dilation, as shown in coronary patients with bezafi-
brate47, and with fenofibrate48 and ciprofibrate49, but



















































































































Fig. 3. – Statins: limited coronary risk reduction when HDL-
C level is low.Fig. 2. – Residual risk in statin trials.
less with gemfibrozil50,51. This could be a consequence
of increased endothelial NO synthase expression, with
an inhibition of inducible NO synthase, providing
antioxidant effects. Fenofibrate also reduces collagen
deposition, preventing cardiac fibrosis in experimen-
tal models52. They reduce the expression of cell adhe-
sion molecules ICAM-1 and VCAM-1 by modulating
the nuclear transcriptor factor NF-κB, lowering at the
same time chemoattractant factors, such as MCP-1,
and inflammation. As a consequence, fenofibrate
decreases several inflammatory factors, such as CRP,
TNFα, CD40, IL-6 and IL-1β 53, the latter two being
also strong procoagulant cytokines. This implies an
inhibitory effect of fenofibrate on haemostasis. Fenofi-
brate also decreases PAI-1, and –in contrast to statins–
also decreases fibrinogen54.
If one considers the various metabolic pathways that
are found to be disturbed in metabolic syndrome and
type 2 diabetes (table 1), it appears that fenofibrate has
beneficial effects on many of those factors involved.
Overall, the atherogenic lipid profile of low HDL-
C, high triglycerides and high small dense LDL levels
is improved. Fenofibrate slightly increases insulin sen-
sitivity, increases adiponectin, decreases thrombogenic
factors, lowers inflammatory markers and improves
endothelial function.
Evidence-based medicine for fibrates
GEMFIBROZIL
In the VA-HIT55 trial on 2531 male coronary
patients with low HDL and LDL cholesterol levels,
gemfibrozil (1200 mg/day) decreased mean plasma
triglycerides by a significant 31% (P < 0.001) and
increased HDL-C by 6% (P < 0.001), while having no
effect on LDL-C and only a minor effect on total cho-
lesterol (–4%) (figure 5). This lipid profile change was
linked to a reduction of the combined endpoint of
[non-fatal MI - cardiovascular mortality - stroke] by a
significant 24% (P < 0.001) versus placebo. Non-fatal
MI decreased by 23% (P = 0.02), stroke decreased by
29% (P = 0.04), among which transient ischaemic
attacks (TIA) were lowered by 59% (P < 0.001) (table 2).
This study shows that without any therapeutic change
of LDL-C, CV morbidity and mortality of coronary
patients can be decreased by changing the lipid profile
towards higher levels of HDL-C and lower triglyceri-
daemia, with a magnitude of protection comparable
to that of major statin trials. The level of benefit was
greatest at the highest tertile of baseline triglycerides56.
In the Helsinki Heart Study57 (HHS), treatment
with 1200 mg gemfibrozil in 4081 asymptomatic men
with dyslipidaemia resulted in an 11% decrease in
LDL-C, a 35% decrease in triglycerides and an 11%
increase in HDL-C versus placebo. All cardiac events
were lowered by 34% (P = 0.02), and non-fatal MI by
37% (P < 0.05), an achievement comparable to what
would be expected from LDL-C lowering with statins.
An 18-year mortality follow-up58 including the 5-year
double-blind period and a 13-year open-label phase
showed a further separation of coronary mortality
curves over time. Adjusted CHD mortality risk was



















































































































Fig. 4. – Fibrates: effects on lipids and other actions.
Table 1. – Cardiovascular risks of metabolic 
syndrome and type 2 diabetes
Lipids: HDL-C ↓ - TG ↑ - small dense LDL-C ↑
Glucose metabolism: Insulin ↑ - glucose ↑
Adipose hormones: leptin ↑ - adiponectin ↓
Thrombogenicity: fibrinogen ↑ - PAI-1 ↑
Inflammation: CRP ↑ - IL6 ↑ - TNFa
Endothelial dysfunction
Fig. 5. – VA-HIT lipid changes.
Table 2. – VA-HIT clinical results.
0.76 (95% CI 0.59-0.99). As in the double-blind phase,
the effect of gemfibrozil on mortality at 18 years was
most striking in overweight patients with baseline high
triglyceride (RR 0.30; 95% CI 0.15-0.58) or low HDL-
C levels. In both trials, multivariate analysis showed a
good correlation between HDL-C increase and thera-
peutic benefit, but a lesser correlation with triglyceride
reduction. The presence or absence of insulin resis-
tance seems even more important for fibrate benefit, as
shown in the VA-HIT trial59. It should be noted that
gemfibrozil is not available in Belgium.
BEZAFIBRATE
The Bezafibrate Infarction Prevention (BIP) study60
explored during 6 years the effects of bezafibrate
(400 mg) versus placebo in 3090 patients with coronary
disease and HDL-C < 45 mg/dL. The most pronounced
effects were a 17.9% increase of HDL-C versus base-
line, and a 20% decrease of triglycerides, with only
minor effects on total or LDL-C. Figure 6 shows those
changes versus placebo. At 6 years, the primary end-
point rate was decreased by 9.4% (NS) and non-fatal
MI by 12.8% (NS). However, it should be noted that
two-thirds of patients randomized to placebo received
open-label lipid-lowering drugs with ability for improv-
ing outcome, making a real comparison of bezafibrate
with “placebo” invalid. When patients were selected
according to triglyceridaemia > 200 mg/dL, the primary
endpoint was lowered by 39.5% (P = 0.02), despite the
bias of added lipid-lowering therapy in the placebo
group. A further post-hoc analysis of 1470 patients
with MetS in the BIP trial61 showed for bezafibrate a
significant 25% reduction in the primary endpoint, a
29% reduction in any MI and a 26% lowering of car-
diac death (figure 7). In patients with augmented fea-
tures of MetS (4/5 or 5/5 scores), cardiac mortality was
dramatically lowered by 56% (P = 0.005).
FENOFIBRATE
Comparative trials of fenofibrate versus statins in
primary dyslipidaemia62 show, as expected, a 17 to 36%
decrease in LDL-C with statins, and for fenofibrate a
30 to 50% decrease of triglycerides and a 1 to 25%
increase in HDL-C. Interestingly, when patient groups
were split up according to initial HDL-C values63, the
effect of fenofibrate on both HDL-C and triglycerides
increase with decreasing baseline levels of HDL-C. By
contrast, the effect of the statin was not only modest
on these lipid fractions, but independent of initial
HDL-C. This confirms earlier findings with other
fibrates and stresses the potential benefit of adding
fenofibrate to patients with low baseline or residual
HDL-C, as, for instance, in MetS and type 2 diabetes.
Clinical trials exploring the combination of fenofi-
brate with statins62,64-66 reported a lowering of LDL-
C by 30 to 41%, a decrease of triglycerides by 39 to
57%, and an increase of HDL-C by 3 to 19%.
Triple therapy with fenofibrate, simvastatin and eze-
timibe, as investigated in 611 patients67 with mixed
hyperlipidaemia (figures 8, 9), decreased LDL-C 45%,
triglycerides 50%, and increased HDL-C 19%. Inter-
estingly, the powerful and beneficial effect on small
dense LDL particles was mainly driven by fenofibrate,
as their proportion decreased from 61% at baseline to
17% after 12 weeks of treatment.
Fibrates studies in diabetic patients
GEMFIBROZIL
Subgroup analysis of the VA-HIT trial68 for 
diabetes (n = 769) showed, as expected, a higher cumu-
lative incidence of major cardiovascular events in the
diabetic group (36.5%) versus the normal fasting 
glucose group (21%). In patients with diabetes, gemfi-
brozil induced a lesser increase of HLD-C (+ 5%
vs. + 8%, P = 0.02) and a lesser decrease in triglycerides



















































































































Fig. 6. – BIP lipid changes.
Fig. 7. – BIP clinical results.
(–20 vs. –29, P < 0.001) than in normal fasting glucose
patients. As in the main trial, LDL-C was not affected.
Diabetic patients showed a greater benefit of gemfi-
brozil treatment with a 32% risk reduction (HR 0.68;
95% CI 0.53-0.88; P = 0.004) than those without dia-
betes (–18%; HR 0.82; 95% CI 0.67-1.02; P = 0.07).
Diabetic individuals had a 41% reduction in CHD
death (HR 0.59; 95% CI 0.39-0.91; P = 0.02) and a
40% reduction in stroke risk (HR 0.60; 95% CI
0.37–0.99; P = 0.046).
In the HHS study, the subgroup of type 2 diabetes
(n = 135) was too small to draw conclusions69, although
a similar trend of benefit for diabetic patients from gem-
fibrozil treatment could be seen as in VA-HIT.
BEZAFIBRATE
For bezafibrate no large-scale outcome studies in
diabetes are available. A small study70 in 164 type 2
diabetic patients followed during 5 years showed a 
significant reduction in the combined incidence of
Minnesota-coded probable ischaemic change on rest-
ing ECG and of documented myocardial infarction.
FENOFIBRATE
In patients with diabetes, fenofibrate was shown to
improve the atherogenic lipid profile and certain
thrombogenic factors. Fenofibrate alone decreased
triglyceride levels by 25 to 28% and increased HDL-
C by 3 to 7% in the two available major studies71,72.
In type 2 diabetes, the combination of fenofibrate
with statins lowered LDL-C by 29 to 46%, triglyc-
erides by 32 to 50% and increased HDL-C by 11 to
34%, making this combination very attractive for this
type of patients62. For patients with MetS, the com-
bination of fenofibrate and simvastatin lowered
triglycerides by 52% and increased HDL-C by 23%.
VLDL and IDL cholesterol were lowered more than
with statin monotherapy73.
When comparing atorvastatin with fenofibrate in
type 2 diabetic patients regarding their effects upon
LDL-particles according to size74, it appeared that
atorvastatin did not change LDL subtype distribution.
The statin had the strongest and significant effect on
the naturally occurring large, buoyant particles (-31%)
and a somewhat less pronounced but still significant
effect on the most atherogenic small dense particles 
(-25%). In contrast, fenofibrate lowered the small dense
particles significantly by 32%, while increasing the
intermediate sized particles and lowering the buoyant
size ones by 24%.
The effect of fenofibrate on atheroma progression
was measured with computer-assisted quantitative
analysis of paired angiograms in the DAIS trial (Dia-
betes Atherosclerosis Intervention Study)71, exploring
418 patients with type 2 diabetes during 3 years. Fenofi-
brate decreased LDL-C 7% and triglycerides 28%,
while increasing HDL-C 8%. As shown in table 3, there
was a significant 40% lesser progression in minimum
lumen diameter and 42% for percentage diameter of
stenotic lesions, reflecting a significant effect on focal
coronary disease. There was also 25% lesser progres-
sion in mean segment diameter, indicating a therapeu-
tic effect on diffuse disease. Although the study was
not designed for hard clinical endpoints (the latter
requiring massive study populations), there was a trend
for lowering morbidity, mortality and invasive inter-
ventions. This study also confirmed the corrective effect
of fenofibrate on LDL particle size75, and the link
between small dense particles and CAD progression.
Regression analysis showed an additive effect of small
LDL to the effect of LDL-C and apo-B on lesion pro-
gression. This study also confirmed the importance of
HDL increase by fenofibrate in stabilisation of
atheroma progression, as demonstrated in multivari-
ate correlation analyses76 of four major statin
atheroma regression studies (ACTIVATE77, ASTER-
OID78, CAMELOT79 and REVERSAL80; β coefficient
–0.26, CI –0.41 to –0.10, P < 0.001).
The Fenofibrate Intervention and Event Lowering
in Diabetes (FIELD) study72 investigated the effects 
of fenofibrate in 9795 patients with type 2 diabetes 
during 5 years. More than 75% of patients were in 
primary prevention. Total cholesterol and LDL-C



















































































































Fig. 8. – Combination fenofibrate + simvastatin + ezetimibe
in mixed dyslipidaemia: effects on lipids.
Fig. 9. – Combination fenofibrate + simvastatin + ezetimibe
in mixed dyslipidaemia: effect on small dense LDL.
decreased by 12%, triglycerides by 30% and HDL-C
increased by 4% at 12 months. By the end of the study,
the differences were 7%, 6%, 22% and 1.2% respec-
tively, partly because of discontinuation of active treat-
ment. These lipid changes resulted in an 11% reduction
in primary endpoint (P = 0.16), inappropriately
obscured by a 17% statin use in the placebo group ver-
sus 8% in the treatment arm. When corrected for this
(not randomised) use in a time-dependent pre-speci-
fied Cox regression analysis, fenofibrate reduced the
risk of coronary disease events by 19% (P = 0.01). For
the 7664 primary prevention patients, cardiac end-
points were reduced by 25% (P = 0.014). There was a
24% reduction in non-fatal myocardial infarction
(P = 0.01), with a non-significant trend in coronary
mortality increase, 15% lesser albuminuria progression
(P = 0.002), 30% lesser laser treatment for retinopathy
(P = 0.0003) and 38% lesser non-traumatic lower limb
amputations (P = 0.04), indicating an effective, clini-
cal relevant and statistical significant protection against
diabetic macrovascular and microvascular complica-
tions (figure 10). In the smaller group of patients in
secondary prevention, no change in risk profile could
be detected, suggesting that fenofibrate could be of
particular benefit in patients with early type 2 diabetes
without CVD.
Further analysis of the effects of fenofibrate on
VLDL and HDL subspecies in a substudy of FIELD81
showed mainly an increase in small dense more vascu-
loprotective HDL3-C ( + 13.0% vs. placebo; 95% CI 7.5-
18.3; P < 0.001) and HDL3-C particle mass ( + 12.5%
vs. placebo; 95% CI 7.2-17.9; P < 0.001) at 5 years ver-
sus baseline and versus placebo, together with a decrease
in HDL2-C (–27.5%; 95% CI 18.3-37.3; P < 0.001) and
HDL2 particle mass (–23.1; 95% CI 13.6-32.2;
P < 0.001). For triglycerides, fenofibrate decreased
mostly the large buoyant VLDL1-TG (–46.5%; 95% CI
31.3-63.2; P < 0.001), but also VLDL2-TG (–33.3%; 95%
CI 20.6-45.8; P < 0.001) and the particle mass of VLDL1
(–43.5%; 95% CI 29.5-59.4; P < 0.001), VLDL2 (–32.5%;
95% CI 20.0-45.3; P < 0.001) and IDL (–12.0%; 95% CI
2.0-21.5; P = 0.019).
Interactions with food
Fibrates do counteract the deleterious effects of
high-fat diet as shown in various animal models82.
Combination of a fibrate with a Mediterranean diet
decreased significantly Lp(a) median values from 36.5
to 8.4 mg/dL, and total cholesterol as well, showing a
positive interaction with hypolipaemiant diets83,84. In a
study in 45 subjects no significant interaction appeared
between food and fenofibrate nano tablets85,86.
Combination of fibrates and statins – safety aspects
Combinations of fibrates and statins have shown
in multiple trials to be effective not only on athero-
genic lipid profile64-66, but both classes have also
demonstrated an effect on atheroma progression (e.g.
ASTEROID78, REVERSAL80, DAIS71). Are all statins
and fibrates equivalent on safety? The answer is no,
and the reason is linked to different metabolism and
pharmacokinetic interactions.



















































































































Table 3. – DAIS: effects of fenofibrate on 
atherosclerotic plaque.
Fig. 10. – FIELD trial: clinical effects of fenofibrate.
Table 4. – Combination fibrate + statin:
incidence of rhabdomyolysis.
Cerivastatin is well known to increase the risk of
rhabdomyolysis, and was withdrawn from the market
for that reason. Table 4 shows the number of reports of
rhabdomyolysis to the American FDA87 between 1998
and 2002. It appeared that the combination of gemfi-
brozil and cerivastatin was linked to 533 reports, cor-
responding to an incidence of 4600 cases per million
prescriptions. On the other hand, the combination of
fenofibrate with cerivastatin was associated with 
14 reports, with an incidence of 140 cases per million
prescriptions. The combination of fenofibrate with
other statins generated only 2 reports over this 4-year
period, corresponding to an incidence of 0.58 cases of
rhabdomyolysis per million prescriptions. Why such a
difference?
Gemfibrozil increases the plasma levels of statins,
with the most pronounced effect for cerivastatin. This
can be explained by inhibition of the cytochrome P450
(CYP) 2C8 and of the glucuronidation pathway of
statins87,88, reducing their metabolism and increasing
as a consequence their plasma levels and area under the
concentration-time curve (AUC), i.e. the amount of
drug available for target tissues (figure 11).
In contrast, fenofibrate does not significantly inter-
act with the kinetic inactivation pathways of statins,
and is therefore much less likely to increase their
plasma concentrations and AUC87,89. This is shown in
figure 12 for cerivastatin87, pravastatin90 and rosuvas-
tatin91, and has also been investigated for simvas-
tatin92,93 and atorvastatin88,93. This lack of pharma-
cokinetic interactions between statins and fenofibrate
has relaxed the recommendations in package leaflets
and allows all statin doses to be used in combination
with fenofibrate88. The recent NCEP guideline update
also supports a lessening of concern regarding this
combination94. Therefore, in patients with mixed
hyperlipidaemia (such as in type 2 diabetes or meta-
bolic syndrome), fenofibrate appears to be the most
appropriate fibrate choice in addition to a statin88. The
AHA/NHLBI Scientific Statement on diagnosis and



















































































































Fig. 11. – Combination gemfibrozil + statins: kinetics.
Fig. 12. – Combination fenofibrate + statins: kinetics.
management of the metabolic syndrome95 specifically
recommends, as secondary target in treating athero-
genic dyslipidaemia, non-HDL-C, and, as tertiary tar-
get, reduced HDL-C. For the former, once LDL-low-
ering therapy is intensified, addition of a fibrate
(preferably fenofibrate) or nicotinic acid is recom-
mended in high-risk patients, and in all patients when
triglycerides > 500 mg/dL (in the latter case, even before
LDL-lowering therapy). For the latter, addition of a
fibrate or nicotinic acid is to be considered, following
maximization of lifestyle therapies, weight reduction
and increased physical activity.
Future perspectives
The Action to Control Cardiovascular Risk in Dia-
betes (ACCORD) trial96 is a randomized, multicentre,
double 2 ≈ 2 factorial design study involving 10 251
high-risk type 2 diabetic patients. It explores the bene-
fits and risk of intensive glucose control, intensive blood
pressure control, and the combination of fenofibrate
with a statin in the management of dyslipidaemia. Its
completion is expected in 2009. In the lipid trial involv-
ing 5518 patients, fenofibrate is compared with placebo
on top of statin therapy. Moreover, the results of the
ACCORD trial could provide substantial direction
regarding the appropriate targets and techniques of risk
factor management for diabetic patients.
Conclusions
• The prevalence of atherogenic dyslipidaemia is
steadily increasing, and each item of the atherogenic
lipid triad (low HDL-C, high triglyceridaemia and
small dense LDL particle number) was shown to
increase the risk of CV morbidity and mortality.
• In patients with such mixed hyperlipidaemia,
statins alone were shown to decrease primarily LDL-
C levels, while having little impact on the atherogenic
triad. As a consequence, the residual risk in patients
with low HDL-C remains high. Although they have
proven to lower significantly CV morbidity and mor-
tality for patients with cardiovascular risk, statins still
leave them with a high residual risk for coronary events
of more than 60%.
• Fenofibrate acts primarily on the components of
the atherogenic lipid triad, and on the various dys-
functional markers associated with a metabolic syn-
drome and type 2 diabetes.
• Fenofibrate was shown to slow down the pro-
gression of atheromatous lesions, and to lower CV end-
points and macrovascular and microvascular compli-
cations of type 2 diabetes.
• The combination of fenofibrate with statins has
proven to be safe and highly potent in lowering LDL-
C, triglycerides, small dense LDL particle numbers,
and in increasing HDL-C in patients with mixed hyper-
lipidaemia.
• It seems therefore logical to consider combining
statins and fenofibrate for patients with mixed hyper-
lipidaemia, metabolic syndrome and/or type 2 diabetes,
with a potential rationale to use fenofibrate for inter-
vening at the level of decreasing residual risk while on
statin therapy. The ACCORD trial will provide fur-
ther clinical prospective evidence for this combination.
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